Solid Biosciences Q1 2026 Earnings Report

Solid Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.40
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Solid Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Solid Biosciences Announcement Details

• Quarter: Q1 2026
• Date: 5/21/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Solid Biosciences (NASDAQ:SLDB) is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials.

Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.